Secaucus, NJ and Raleigh, NC – May 4, 2023 – Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced nationwide availability of the RestoreU™ Dementia Panel, a risk assessment and care plan service created by uMETHOD Health, a health technology company specializing in precision medicine for chronic diseases, to help physicians close care gaps for patients with cognitive decline. The RestoreU service employs artificial intelligence…READ MORE
The Latest
Quest Diagnostics Extends Alzheimer’s Disease Portfolio with New AI-Powered Test Service from uMETHOD Health
May 4, 2023
uMETHOD Health, a precision-medicine software company based in the Research Triangle of North Carolina, is pleased to announce enhancements to their customized care plans that streamline the process for administering cognitive care. The new features consist of eight checklist-style “compliance elements.” These components assist physicians in completing the required service elements for the Cognitive Assessment and Care Plan (CACP) developed by the U.S. Centers for Medicare and Medicaid Services (CMS).…READ MORE
Quest Diagnostics and uMETHOD Health, Inc. are excited to announce the national launch of a robust solution in the fight against dementia. Using a 3-step approach that combines our advanced testing with uMETHOD’s AI-based technology, you can help patients prevent cognitive decline, improve brain health, and maintain independence. Learn more about Quest Diagnostic's Alzheimer's disease testing portfolio at Questforthecure.com or contact a uMETHOD Health representative today.…READ MORE
Studies Show Links Between Chronic Kidney Disease and Memory Loss, What Can You Do About It?
March 27, 2023
World Kidney Day has been observed in early March since 2006; in the US, March is National Kidney Month. Efforts to increase awareness of kidney health are timely, as chronic kidney disease (CKD) affected an estimated 37 million Americans in 2021. Drugs prescribed for common illnesses can increase the risk or severity of CKD. This risk comes in addition to drug-to-drug interactions (DDIs) that might also exacerbate CKD. And unfortunately,…READ MORE
Recent News of Bruce Willis’s Frontotemporal Dementia Diagnosis Raises Questions About Available Treatments
March 6, 2023
Frontotemporal Dementia (FTD) is a neurodegenerative disease that affects two brain structures: the frontal lobes and the temporal lobes. The location of damage is distinct from that of Alzheimer’s Disease (AD), which is characterized by the degeneration of the brain structure known as the hippocampus. For each of these conditions, neurodegeneration can be readily quantified by the amount of shrinkage (loss of tissue) in these structures, which can be observed…READ MORE
Today’s standard of care for complex diseases like Alzheimer’s Disease (AD) and related dementias fails to meet the needs of an aging patient population. It falls short of providing adequate guidance for clinicians who bear the burden of this care gap. Complex diseases proceed from many contributing factors -- medical, genetic, and environmental -- that vary widely from person to person. Untangling the web of factors that contribute to neurodegeneration can…READ MORE
In February 2022, Dr. Federico Canavosio of Integrative Medical Care (IMC) in Vero Beach, FL started applying a new approach to memory care for patients aged 60 and older. IMC began working with medical AI company uMETHOD Health to deploy RestoreU, an evidence-based care program for patients at risk of developing Alzheimer’s Disease (AD), dementia, or other cognitive issues. “Cognitive impairment and related dementias are difficult to treat because they…READ MORE
Despite our annual expressions of gratitude to our veterans for all they’ve sacrificed, we fall short when it comes to their health and well-being. In addition to cancer, diabetes, and mental-health disorders, veterans suffer from Alzheimer’s Disease (AD) and other forms of dementia at high rates. Veterans currently under a physician’s care need a comprehensive workup and a care plan that addresses the factors that drive the progression of AD.…READ MORE
PathGroup and uMETHOD Health Partner to Personalize Care for Mild Cognitive Impairment (MCI) and Early-stage Alzheimer’s Disease Patients
November 10, 2022
NASHVILLE, Tenn., Nov. 9, 2022 /PRNewswire/ -- uMETHOD Health, a health technology company specializing in precision medicine for complex diseases, announces a partnership with PathGroup, one of largest independent laboratories in the United States. uMETHOD's AI-based care planning solution, RestoreU, pairs comprehensive testing from PathGroup with actionable treatment recommendations, aimed at lowering patient's risk of developing Alzheimer's and disease progression in its early stages. Read the full release.…READ MORE
What’s the connection between Alzheimer’s Disease (AD) and falls among senior adults?
September 21, 2022
uMETHOD Health is partnering with regional and national diagnostic laboratories and hundreds of physicians to identify and address the multiple factors that contribute to cognitive issues in seniors. The Raleigh, NC-based company produces leading-edge medical artificial intelligence (AI) and services to target complex diseases such as Alzheimer’s Disease (AD). On the 29th annual World Alzheimer’s Day, uMETHOD states there are multiple contributors involved in the progression of AD and they…READ MORE